Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265855 | 0.78 | TLR8 (0.36) | TLR8 | |
| SCHEMBL1064791 | 0.69 | HRH3 (0.41) | — | |
| SCHEMBL2270797 | 0.67 | ALDH1A1 (0.37) | — | |
| SCHEMBL1061184 | 0.67 | SIGMAR1 (0.41) | TLR8 | |
| SCHEMBL30886917 | 0.65 | SMN1; SMN2 (0.57) | TAAR1 | |
| SCHEMBL8950010 | 0.62 | ALDH1A1 (0.50) | TAAR1 | |
| SCHEMBL8950158 | 0.61 | APP (0.47) | — | |
| SCHEMBL11757551 | 0.61 | TAAR1 (0.41) | NOS1TAAR1 | |
| Hydrochloric Acid SCHEMBL11760185 | 0.60 | TAAR1 (0.40) | TAAR1 | |
| SCHEMBL31173760 | 0.59 | CYP2D6 (0.55) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015185-A1 | Benzofuran Compounds | BIOVITRUM AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-7820675-B2 | Benzofuran compounds | BIOVITRUM AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-20060287291-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1694663-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | Biovitrum Aktiebolag (SE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058858-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | BIOVITRUM AB (SE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287291-A1 | Compounds | HTR6, HTR1B, HTR1A | TLR8 2221/4885NOS3 1111/4885NOS1 1299/4885 |
| US-20110015185-A1 | Benzofuran Compounds | HTR6, HTR1F, HTR1A | TLR8 1508/4885NOS3 1329/4885NOS1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.